AIDS:
24 September 2010 - Volume 24 - Issue 15 - p 2375–2380
doi: 10.1097/QAD.0b013e32833dfad1
Clinical Science
Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation
Tosini, Williama,b; Muller, Philippec; Prazuck, Thierryd; Benabdelmoumen, Ghaniab; Peyrouse, Erice; Christian, Bernardc; Quertainmont, Yannf; Bouvet, Elisabetha,b; Rabaud, Christiana,c
Author Information
aGroupe d'Etude sur le Risque d'exposition des Soignants aux Agents Infectieux (GERES), France
bHôpital Bichat Claude-Bernard, Paris, France
cCOREVIH Lorraine Champagne Ardenne, Centre Hospitalier et Universitaire, Nancy, France
dCentre Hospitalier Régional, Orléans, France
eHôpital Sainte Marguerite, Marseille, France
fHôpital Bicêtre, Paris, France.
Received 8 September, 2009
Revised 1 July, 2010
Accepted 6 July, 2010
Correspondence to Dr William Tosini, GERES, Université Paris Diderot Paris 7, UFR de Médecine site Bichat, 16 rue Henri Huchard, 75890 Paris Cedex 18, France. E-mail: wilto@libero.it
Abstract
Objective: To evaluate the tolerability of HIV postexposure prophylaxis (PEP) with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation (TDF/FTC+LPV/r).
Design: Multicentric observational prospective study.
Method: Adults with an HIV transmission risk in the past 48 h were eligible. Baseline sociodemographic characteristics, description of exposure event, and HIV serostatus of the source patient were collected. Laboratory monitoring for toxicity and a clinical evaluation were performed; adherence and side effects were recorded using a standardized form on day 0, 15, and 28.
Results: Between November 2006 and June 2008, 249 participants were included in 10 French hospitals. Mean age was 31.5 ± 10 years. Sex ratio male/female was 1.96. Exposure events are as follows: occupational exposure, 40 (16%); sexual intercourse, 204 (82%); and other, 5 (2%). Tolerability could be evaluated in 188 cases. In 22 cases, PEP was discontinued for adverse effects before day 28, including two cases of skin rash related to TDF/FTC prescription, one renal lithiasis related to LPV/r prescription, and one rhabdomyolysis. One hundred and sixty-six persons completed the 28 days of PEP with tolerability judged as good in 96 (58%) individuals. Among everyone who experienced at least one side effect, 78% reported diarrhea, 78% asthenia, and 59% nausea and/or vomiting.
Conclusion: Considering data of previous studies performed using similar methodology, the dropout rate due to adverse events appeared significantly lower in TDF/FTC+LPV/r tablet formulation than those in zidovudine/lamivudine (ZDV/3TC)+nelfinavir (P < 0.0001), ZDV/3TC+lopinavir/ritonavir soft gel capsules (P < 0.01), and 3TC+TDF+atazanavir boosted by ritonavir (P < 0.05) and should be considered as standard of care concerning HIV PEP.
I have long felt a special connection with herbal medicine. First, it's natural, Charlie attended the same small college in Southern California - Claremont Men's College - although he dropped out of school to enroll in the Julliard School of Performing Arts in New York. York. Had he been to Claremont, he would have been senior the year I started there; I often thought that was the reason he was gone when he discovered that I had herpes. So, my life was lonely, all day, I could not stand the pain of the outbreak, and then Tasha introduced me to Dr. Itua who uses her herbal medicines to cure her two weeks of consumption. I place an order for him and he hands it to my post office, then I pick it up and use it for two weeks. All my wound is completely healed no more epidemic. I tell you honestly that this man is a great man, I trust him Herbal medicine so much that I share this to show my gratitude and also to let sick people know that there is hope with Dr. Itua. Herbal Phytotherapy.Dr Itua Contact Email.drituaherbalcenter@gmail.com/Whatsapp ... 2348149277967
ResponderEliminarHe cures.
Herpes,
Prostate
Breast Cancer
Brain Cancer
CEREBRAL VASCULAR ACCIDENT.
,Endomertil Cancer, cerebrovascular diseases
Hepatitis,Glaucoma., Cataracts,Macular degeneration,Cardiovascular disease,Lung disease.Enlarged prostate,Osteoporosis.Alzheimer's disease,
Dementia.Tach Disease,Shingles,
Lung Cancer, Leukemia Lymphoma Cancer,
Lung Mesothelioma Asbestos,
Ovarian Cervical Uterine Cancer,
Skin Cancer, Brain Tumor,
H.P.V TYPE 1 TYPE 2 TYPE 3 AND TYPE 4. TYPE 5.
HIV,Arthritis,Amyotrophic Lateral Scoliosis,Fibromyalgia,Fluoroquinolone Toxicity
Cervical Cancer
Colo-rectal Cancer
Blood Cancer
SYPHILIS.
Diabetes
Liver / Inflammatory kidney
Epilepsy